INTRODUCTION
Direct-to-consumer advertising (DTCA) is the marketing and promotion of pharmaceuticals or medical services to the public through lay media. Despite the diminishing use of DTCA in recent years, pharmaceutical companies still spent $4.3 billion on such promotion in 2010. 1 Opponents of DTCA argue that it leads to overdiagnosis, unnecessary and inappropriate prescribing, more adverse drug reactions, and increased healthcare costs. [2] [3] [4] Proponents, on the other hand, maintain that it raises public awareness of underdiagnosed diseases and leads to appropriate increases in diagnostic testing and treatment. 5 Thus far, the limited evidence-of varying methodological quality-on the effects of DTCA is inconclusive. 6 Numerous studies have investigated the impact of DTCA on prescription drug use. Previous time series analyses have shown that DTCA was associated with increased volume of prescriptions for tegaserod (the only available medication for irritable bowel syndrome), antihistamines (first-line therapy for allergic rhinitis), statins (hyperlipidemia), histamine H 2 -receptor antagonists (acid reflux), triptans (migraine), and terbinafine (onychomycosis). [6] [7] [8] [9] [10] In contrast, DTCA for drugs such as etanercept (for symptom refractory rheumatoid arthritis), mometasone (second-line therapy for allergic rhinitis), and clopidogrel (anti-platelet agent for acute coronary syndrome or following percutaneous intervention) have not been shown to alter prescribing rates. 7, 11 Overall, it appears from the existing body of evidence that when DTCA has been shown to increase prescribing volume, it typically involves greater use of medications for common and underdiagnosed diseases.
In this context, it remains unknown how the many DTCA campaigns affect competing medications. For example, a DTCA campaign that led to an increase in prescriptions for first-line therapy of an undertreated condition might be considered beneficial, whereas greater use of second-line therapy could be considered wasteful and counterproductive. To our knowledge, no prior study has investigated the effect of DTCA campaigns for drugs from different pharmaceutical classes but for the same therapeutic indication. While some research has suggested a "class effect," 12 no prior study has investigated the comparative effect of DTCA on consumer interest and utilization of first-line versus second-line therapies. During the peak period of DTCA spending, two medications for benign prostatic hyperplasia (BPH), dutasteride and tamsulosin, were sequentially marketed, providing a unique opportunity to study the relationship between two campaigns for different drugs that treat the same symptomatic disease. Thus, we investigated the effect of two sequential DTCA campaigns for dutasteride and tamsulosin on both patient interest and prescription volume.
METHODS

Study Drugs
Lower urinary tract symptoms in men are most commonly attributed to BPH by treating physicians. 13 In men, the prevalence of moderate to severe lower urinary tract symptoms increases with age-affecting over one-third of men over the age of 65. However, only 10 % of men with such symptoms are treated with prescription medications. 14, 15 As BPH is underdiagnosed and undertreated, the potential exists for large market expansion through DTCA. 15 Medical therapy for BPH includes alpha 1-adrenergic antagonists (alphablockers), 5-alpha reductase inhibitors (5ARIs), or both in combination. In 2003, the American Urological Association published recommendations for the management of BPH in patients seeking medical treatment. 16 The guidelines stated that alpha-blockers were more effective than 5ARIs in improving lower urinary tract symptoms in men with BPH. Comparatively, 5ARIs were known to lead to more sexual side effects and were only considered effective in men with clinical evidence of prostatic enlargement. Due to their efficacy and rapid effect, alpha-blockers were considered first-line therapy for men with BPH. 17 Starting in 2005, two drugs prescribed for BPH were heavily marketed through national DTCA campaigns. Tamsulosin (Flomax ® ) is an alpha-blocker that acts by relaxing the prostatic smooth muscle to relieve bladder outlet obstruction. Compared to other alpha-blockers, tamsulosin is the most uroselective (alpha-1A) and has fewer systemic adverse effects than other drugs in its class. 18, 19 Dutasteride (Avodart ® ) is a 5ARI that blocks the conversion of testosterone to dihydrotestosterone, leading to a reduction in the size of the prostate and improving urinary function. Dutasteride acts on both 5-alpha reductase isoenzymes (types 1 and 2), resulting in a greater reduction in systemic dihydrotestosterone compared to the other available 5ARI, finasteride. 20 
Data Sources
Advertising Spending. To determine total DTCA expenditures for tamsulosin and dutasteride, we followed previous studies and used monthly estimates of national advertising expenditures from Kantar Media/TNS Media Intelligence for the period from January 2003 through December 2007. 7, 21, 22 Web Search Interest. To measure the effect of the DTCA campaigns on consumer interest and response, we analyzed trends in search volumes from Google. We focused on online searches, as surveys have found that 80 % of U.S. adult Internet users sought health information online in 2005 and 2006. 23, 24 Google, which is the most widely used Internet search engine in the world, was used for almost half of U.S. online searches at the time that BPH advertising began. 25 Google Trends charts the volume of searches for particular terms over time. 26 The available data is normalized and scaled from 0 to 100, with 100 representing the month with the highest search volume during the period. As both DTCA campaigns advertised the brand names of the medicines, we obtained monthly data on searches for "Avodart" and Drug Utilization. We obtained monthly U.S. prescription rates from IMS Health, a leading provider of market intelligence to the pharmaceutical and health care industries, through their National Prescription Audit database. 27 This database estimates national prescription activity at retail, mail-order, long-term care, and managed care outlets based on a sample of 70 % of all outlets. 28, 29 As both drugs are predominantly prescribed at fixed dosage strengths, we examined changes in the number of units sold. Monthly rates of units dispensed were obtained for tamsulosin and dutasteride for the periods from January 2003 through December 2007 in order to ensure a 36-month window around the start of each DTCA campaign.
Statistical Analysis
We used interrupted time series analysis, one of the strongest quasi-experimental designs, to study the impact of the two sequential DTCA campaigns on the longitudinal trends in the use of dutasteride and tamsulosin. 30 We examined the number of units per 1,000 U.S. population per month for each drug to assess changes in use before and after DTCA initiation. National estimates for the number of units dispensed per 1,000 people were obtained by dividing monthly estimates by the U.S. population and multiplying by 1,000.
31
Time series models were fitted to assess for changes in the level (step) and trend (slope) in the study outcomes (Internet search volume, number of units dispensed) for each drug following the start of each of the two DTCA campaigns. This method controls for existing trends in use prior to DTCA. The start dates for the two DTCA campaigns for dutasteride and tamsulosin were July 2005 and April 2006, respectively. A generalized least-squares model was used, and included autoregressive terms to control for correlation over time. Two binary variables indicating the post-DTCA periods for each drug were used to assess changes in level, and a variable indicating the number of months elapsed since DTCA had begun was used to assess changes in trend. Autocorrelation, partial autocorrelation, and inverse autocorrelation functions were assessed for model/parameter appropriateness and seasonality. Stationarity was assessed using the autocorrelation function and the augmented Dickey-Fuller test. The presence of "white noise" was assessed by examining the autocorrelation values at various lags using the Ljung-Box X 2 statistic.
RESULTS
Total DTCA spending for these two competing drugs was $369.9 million over the time period studied: $231 million for dutasteride and $139 million for tamsulosin. Average monthly spending on DTCA for dutasteride and tamsulosin from the start of their campaigns through December 2007 was roughly comparable, at $6.6 million and $7.7 million per month, respectively (Fig. 1) .
Web Search Interest
Both DTCA campaigns were associated with increased volume of Internet searches for their respective drugs (Fig. 2) . The dutasteride campaign was associated with an increase in search level for the target drug "Avodart" of 31. 
Use of Study Drugs
Avodart Campaign (July 2005). As shown in Fig. 3 
DISCUSSION
Over the last 15 years, pharmaceutical manufacturers have spent many billions of dollars on advertising campaigns directed at consumers. 1 Our study lends further credence to previous results indicating that DTCA is effective in increasing the utilization of drugs for common but underdiagnosed diseases. Further, our study suggests that the impact of DTCA campaigns is heavily influenced by the clinical context in which they occur, as we found that the advertising campaign for one drug, despite raising consumer interest in the targeted drug, had a larger impact on prescribing patterns for a competing first-line drug. These findings shed light on mechanisms along the pathway necessary for DTCA to be effective. Upon seeing an advertisement for a drug, the consumer (or patient) must be motivated enough to schedule a visit and seek out a prescription for the relevant symptoms from his or her physician. Further, once the patient is in the physician's office, after a careful history and physical (including a digital rectal examination in this setting), the choice of medication to prescribe is at the discretion of the physician, guided by the overall clinical context as well as patient expectations and preferences. As such, an increase in prescriptions for nonadvertised medications for the same disease is entirely plausible.
In our study, we found that the Avodart campaign was associated with an increase in tamsulosin (Flomax) prescriptions almost twice that of the effect observed with dutasteride (Avodart) itself, and this was unexpected. Based on Google search volumes for each drug's trade name, both campaigns influenced consumer response, suggesting that this finding was not based on an ineffective Avodart campaign. There are at least two possible explanations for our results. The first, more plausible explanation is that upon requesting dutasteride from their doctor, patients were appropriately prescribed tamsulosin as an accepted first-line medical therapy for men with moderate to severe lower urinary tract symptoms. The second, less likely possibility is that upon researching dutasteride, patients may have explored other medications for symptomatic BPH and subsequently chosen tamsulosin due to its greater efficacy, better side effect profile, and guideline recommendation. The increase in the level of searches for "Flomax" at the beginning of the dutasteride (Avodart) campaign supports this possibility. Implicit in claims that DTCA leads to inappropriate prescribing is the belief that the preferences and requests of the patient-or consumer-will strongly influence the medical judgment of the prescribing physician. However, clinical and professional standards oblige physicians to follow accepted practice and medical guidelines to determine the appropriateness of a medication for each patient on a case-by-case basis. Evidence thus far of DTCA leading to inappropriate prescriptions is limited and has recently been contested. For example, in a select patient population, Abel et al. recently concluded that DTCA led to an appropriate increase in aromatase inhibitor prescriptions in postmenopausal but not premenopausal women. 21 In a randomized trial using standardized patients, Kravitz et al. found that both brand-specific and general antidepressant requests from patients led to increased diagnosis, prescribing, and appropriate care for depression compared to patients with similar symptoms who did not request a prescription. 32 The prevalence in the U.S. of untreated men with moderate to severe lower urinary tract symptoms suggests a large consumer base of men that meet the AUA guidelines for medical therapy of symptomatic BPH. In addition, the relative increase in tamsulosin prescriptions compared to dutasteride prescriptions following both DTCA campaigns suggests that (1) awareness of disease and treatment options increased, and (2) physicians were treating men according to available guidelines that recommend alpha-blockers as initial therapy. Furthermore, medical therapy for BPH has been shown to improve quality of life, reduce the risk of clinical progression, and avert the potential postoperative morbidity and complications of surgical treatment. 15, 33 In aggregate, this suggests to us that issues of overdiagnosis and inappropriate treatment (the main concerns put forward by opponents of DTCA) are unlikely in the case of men with symptomatic BPH.
Limitations
Despite its strengths, there are several limitations that must be acknowledged when interpreting the results of our study. First, this was an observational study of ecologic data, and therefore we cannot definitively conclude that there was a causal relationship between the DTCA campaigns and changes in Internet search and dispensed prescription levels. However, short of a randomized trial of DTCA, which would be prohibitive from a cost perspective, interrupted time series analysis is as close to causal inference as can be drawn from a nonrandomized study. 30 Second, we have no individual patient data, such as indication, previous use, allergy or intolerance, or other medical history. We are also unable to ascertain whether men were using dual therapy with both drugs. Third, we assumed that individual physicians were aware of medical treatment guidelines, and whether physicians themselves were influenced by DTCA itself rather than by patient requests is not clear. Fourth, tamsulosin was approved four years before the approval of dutasteride, and may have been a more accepted and established medication at the time of the DTCA campaigns, although this would be accounted for in the baseline trends. Fifth, we cannot determine whether the results would be similar if the order of the campaigns were reversed. Finally, this study focused on a single disease involving men, and thus the results may not be more broadly generalizable.
CONCLUSIONS
DTCA can have both intended and unintended effects on the prescription rates of drugs that compete with each other but belong to the same therapeutic class. This study suggests that DTCA may be effective in increasing treatment rates for common and underdiagnosed diseases such as benign prostatic hyperplasia (BPH). However, the effect of DTCA appears to be tempered by accepted medical practice and guidelines, and whether it leads to increased diagnosis and better management or overdiagnosis and over-treatment has to be determined on a condition-by-condition basis. For men with lower urinary tract symptoms related to BPH, DTCA on the whole was associated with an increase in the use of a treatment that was-at least in terms of the drug prescribed-in accordance with medical guidelines at the time.
